Tag: BIO TECH

Scisparc Ltd. (Nasdaq: SPRC) has achieved positive results in a preclinical trial observing the safety and impact of a combination treatment on various metabolic and… [Read More]

Redhill Biopharma (Nasdaq: RDHL) has been granted five years’ market exclusivity for Talicia under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product… [Read More]

Surgical robotics innovator, SS Innovations International, Inc.  (OTC: SSII) has successfully performed 500 surgeries using its flagship SSi Mantra Surgical Robotic System. The 500th surgery… [Read More]

Lexaria Bioscience (Nasdaq: LEXX) has demonstrated that its DehydraTECH technology improves the performance of GLP-1 drug, semaglutide, in a human pilot study. DehydraTECH-powered semaglutide achieved… [Read More]

Alzamend Neuro, Inc. (Nasdaq: ALZN) has received a “Study May Proceed” letter from the FDA for the initiation of study AL001-MDD01, a Phase 2a clinical… [Read More]

BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI) will meet with the FDA to discuss the regulatory path forward for NurOwn® in amyotrophic lateral sclerosis (ALS) on… [Read More]

Pharmaceutical company, MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) has entered an exclusive licensing agreement with MIRALOGX, giving it the exclusive rights to develop and commercialize Ketamir-2… [Read More]

MediciNova, Inc. (Nasdaq: MNOV) has presented new data and results of a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients at the… [Read More]

BioVie Inc. (NASDAQ: BIVI) has announced announced positive clinical safety data from the Company’s Phase 2b open-label study evaluating the efficacy and safety of BIV201… [Read More]

Medical technology company, Neuronetics, Inc. (NASDAQ: STIM), announced significant updates to its NeuroStar software and TrakStar® Patient Data Management System, a proprietary, HIPAA-compliant, patient management… [Read More]

SciSparc Ltd (Nasdaq: SPRC) has  announced positive topline results from its investigator-initiated Phase IIa trial evaluating its proprietary SCI-110 treatment for Alzheimer’s agitation. The trial… [Read More]

Chemomab Therapeutics Ltd. (Nasdaq: CMMB) has received FDA Fast Track Designation for CM-101 for the treatment of primary sclerosing cholangitis  (PSC). PSC is a progressive,… [Read More]